Product Description:-
 
Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death.
 
Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen.